Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro

Biochemical and Biophysical Research Communications

Volumn 317, Issue 4, 2004, Pages 965-971

  Wang, Jian Hua ^a,c   Tam, Siu Cheung ^b   Huang, Hai ^b   Ouyang, Dong Yun ^a,c   Wang, Yuan Yuan ^a,c   Zheng, Yong Tang ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Antiviral activity; HIV 1; Polyethylene glycol; Ribosome inactivating protein; Trichosanthin

Indexed keywords

AMINO ACID DERIVATIVE; ANTIVIRUS AGENT; MACROGOL; TRICHOSANTHIN;

ANTIGENICITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; GLYCOSIDATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MASKING; MATHEMATICAL MODEL; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; CELL SURVIVAL; HIV CORE PROTEIN P24; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; POLYETHYLENE GLYCOLS; RABBITS; RIBOSOMES; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TRICHOSANTHIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1942484412     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.03.139     Document Type: Article

References (27)

1. Wang Y. Trichosanthin. second ed. 2000;Science press, Beijing, China.
2. Shaw P.C., Chan W.L., Yeung H.W., Ng T.B. Minireview: trichosanthin a protein with multiple pharmacological properties. Life Sci. 55:1994;253-262.
3. Zheng Y.T., Chan W.L., Chan P., Huang H., Tam S.C. Enhancement of the anti-herpetic effect of trichosanthin by acyclovir and interferon. FEBS Lett. 496:2001;139-142.
4. McGrath M.S., Hwang K.M., Caldwell S.E., Gaston I., Luk K.C., Wu P., Ng V.L., Crowe S., Daniels J., Marsh J., Deinhart T., Lekas P.V., Vennari J.C., Yeung H.W., Lifson J.D. GLQ223: an inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte lineage. Proc. Natl. Acad. Sci. USA. 86:1989;2844-2848.
5. Byers V.S., Levin A.S., Malvino A., Waiter L., Robins R.A., Baldwin R.W. A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. AIDS Res. Hum. Retroviruses. 10:1994;413-420.
6. Byers V.S., Levin A.S., Waites L.A., Starrett B.A., Mayer R.A., Clegg J.A., Price M.R., Robins R.A., Delaney M., Baldwin R.W. A phase I/II study of trichosanthin treatment of HIV disease. AIDS. 4:1990;1189-1196.
7. Kahn J.O., Gorelick K.J., Gatti G., Arri C.J., Lifson J.D., Gambertoglio J.G., Bostrom A., Williams R. Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex. Antimicrob. Agents Chemother. 38:1994;260-267.
8. Chan W.L., Shaw P.C., Li X.B., Xu Q.F., He X.H., Tam S.C. Lowering of trichosanthin immunogenicity by site-specific coupling to dextran. Biochem. Pharmacol. 57:1999;927-934.
9. Bonora G.M., Ivanova E., Zarytova V., Burcovich B., Veronese F.M. Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides. Bioconjug. Chem. 8:1997;793-797.
10. Inada Y., Furukawa M., Sasaki H., Kodera Y., Hiroto M., Nishimura H., Matsushima A. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 13:1995;86-91.
11. Hershfield M.S. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum. Mutat. 5:1995;107-112.
12. Kodera Y., Sekine T., Yasukohchi T., Kiriu Y., Hiroto M., Matsushima A., Inada Y. Stabilization of L-asparaginase modified with comb-shaped poly (ethylene glycol) derivatives, in vivo and in vitro. Bioconjug. Chem. 5:1994;283-286.
13. Katre N.V., Knauf M.J., Laird W.J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA. 84:1987;1487-1491.
14. Tsutsumi Y., Tsunoda S., Kamada H., Kihira T., Kaneda Y., Ohsugi Y., Mayumi T. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb. Haemost. 77:1997;168-173.
15. Tsunoda S., Ishikawa T., Yamamoto Y., Kamada H., Koizumi K., Matsui J., Tsutsumi Y., Hirano T., Mayumi T. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent. J. Pharmacol. Exp. Ther. 290:1999;368-372.
16. Harker L.A., Marzec U.M., Novembre F., Sundell I.B., Waller E.K., Karpatkin S., McClure H.M., Kelly A.B., Stead R.B. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood. 91:1998;4427-4433.
17. Beauchamp C.O., Gonias S.L., Menapace D.P., Pizzo S.V.A. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal. Biochem. 131:1983;25-33.
18. Humphries J., Lattimer C., Smith A., McGuinness C.L., Whitton C., Gaffney P.J., Burnand K.G. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery. Thromb. Res. 87:1997;123-129.
19. Kajihara J., Shibata K., Nakano Y., Nishimuro S., Kato K. Physicochemical characterization of PEG-PPG conjugated human urokinase. Biochim. Biophys. Acta. 1199:1994;202-208.
20. Ajisaka K., Iwashita Y. Modification of human hemoglobin with polyethylene glycol: a new candidate for blood substitute. Biochem. Biophys. Res. Commun. 97:1980;1076-1081.
21. Tang W., Chang Y., Xu L.F., Zheng Z.C., Liu X.Y. Studies on the PEGylation of protein at a specific site: sulfhydryl-PEGylation of 97Cys-IFN-gamma. Acta Biochim. Biophys. Sin. 28:1996;312-315.
22. He X.H., Shaw P.C., Xu L.H., Tam S.C. Site-directed polyethylene glycol modification pf trichosanthin: effects on its biological activity, pharmacokinetics, and antigenicity. Life Sci. 64:1999;1163-1175.
23. Zheng Y.T., Ben K.L. The foundation of MTT method to assess the viability and proliferation of cells. J. Immunol. 8:1992;208-266.
24. Wang J.H., Nie H.L., Tam S.C., Huang H., Zheng Y.T. Anti-HIV-1 property of trichosanthin correlates with its ribosome inactivating activity. FEBS Lett. 531:2002;295-298.
25. Chan W.L., Zheng Y.T., Huang H., Tam S.C. Relationship between trichosanthin cytotoxicity and its intracellular concentration. Toxicology. 177:2002;245-251.
26. Wang J.H., Nie H.L., Tam S.C., Huang H., Zheng Y.T. Independency of anti-HIV activity from ribosome inactivating activity of trichosanthin. Biochem. Biophys. Res. Commun. 302:2003;89-94.
27. He X.H., Shaw P.C., Tam S.C. Reducing the immunogenicity and improved the in vivo activity of trichosanthin by site-directed PEGylation. Life Sci. 65:1999;355-368.